Other major studies, however, have focused on renal inhibition of sodium-glucose cotransporter 2 inhibitor (SGLT2) in the context of CRS, including DECLARE-TIMI 58 (Dapagliflozin Effect on CardiovasculAR Events), CANVAS (Canagliflozin Cardiovascular Assessment Study Program), and EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes) 8-10. Here, SLC5A2 is linked to type 2 diabetes mellitus.